Overcoming Acquired Resistance Mechanisms in BRAF+ mCRC

Video

Following their discussion on data from the BEACON and ANCHOR trials, experts look towards the future and the potential of overcoming acquired resistance mechanisms in the treatment of BRAF-mutated metastatic colorectal cancer.

Related Videos
Pashtoon Murtaza Kasi, MD, MS
Michael Iglesia, MD, PhD
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Jin Qian, PhD
A panel of 4 experts on colorectal cancer
Heinz-Josef Lenz, MD, FACP
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Michael Iglesia, MD, PhD
Kian-Huat Lim, MD, PhD
Related Content
David Eagle, MD, chair, legislative affairs and patient advocacy, New York Cancer & Blood Specialists; chair, Advocacy Committee, OneOncology

Leveraging Managed Service Organizations to Provide More Affordable, Personalized Cancer Care

May 17th 2024
Article
Gina Z. D’Amato, MD

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023
Podcast
Timothy L. Cannon, MD

Pertuzumab Plus Trastuzumab Surpasses Prespecified Activity Threshold in ERBB2/3-Altered Biliary Tract Cancer

May 15th 2024
Article
John H. Strickler, MD

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023
Podcast
Susanna Hegewisch-Becker, MD, PhD

Relatlimab Plus Nivolumab/Chemo Misses ORR End Point in LAG-3+ Advanced Gastric/GEJ Cancer

May 14th 2024
Article
Benjamin A. Weinberg, MD

Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy

May 10th 2024
Article